Table 3.
Number and proportions of patients with OI ≥ 2-fold increase at week 5 in PCV-13 serotypes by subgroup
| Serotype 4 | Serotype 6B | Serotype 14 | Serotype 23F | |
|---|---|---|---|---|
| Overall baricitinib group (N = 106) | 74 (76) | 76 (76) | 47 (47) | 73 (73) |
| Concomitant corticosteroids | ||||
| Yes (N = 31) | 27 (87) | 26 (84) | 14 (45) | 20 (65) |
| No (N = 72) | 47 (70) | 50 (72) | 33 (48) | 53 (77) |
| Age group | ||||
| Patients < 65 years (N = 80) | 61 (81) | 66 (86) | 40 (52) | 58 (75) |
| Patients ≥ 65 years (N = 23) | 13 (57) | 10 (43) | 7 (30) | 15 (65) |
| SDAI prior to vaccination | ||||
| ≤ 3.3 (N = 21) | 14 (70) | 16 (76) | 11 (52) | 16 (76) |
| > 3.3 and ≤ 11 (N = 47) | 36 (82) | 34 (76) | 24 (53) | 29 (64) |
| > 11 (N = 32) | 23 (74) | 25 (81) | 11 (35) | 26 (84) |
| Dose | ||||
| 2 mg (N = 16) | 11 (73) | 11 (73) | 9 (60) | 9 (60) |
| 4 mg (N = 87) | 63 (76) | 65 (76) | 38 (45) | 64 (75) |
Data are reported as n (%)
OI opsonization index, PCV-13 13-serotype pneumococcal conjugate vaccine, SDAI Simple Disease Activity Index